KFDA approves another indication for Enbrel

Wyeth Korea said the Korea. Food and Drug Administration approved Enbrel in October 28 to treat severe ankylosing spondylitis (AS). The drug, marketed by Amgen and Wyeth Pharmaceuticals, is already approved to treat rheumatoid arthritis.

Enbrel is the first biologic drug approved to treat the signs and symptoms in patients with active AS who have had an inadequate response to one or more dis...